Leading the Way in Effective Drug Development
Substance Use Disorder Trial Deploys App for Treatment Adherence and Collection of Daily Subject Reports on Drug and Alcohol Use
Research into substance use disorder treatments is complex and evolving, uniquely shaped by scientific advancements, societal attitudes, and the changing nature of substance use disorders themselves. Patients with substance use disorders often exhibit poor medication adherence, which can lead to inconsistent treatment outcomes and reduced effectiveness of the tested medication. Substance abuse can directly and indirectly impact medication compliance, as active substance use or association with substance users can lead to disorganized lifestyles and reduced focus on adhering to medication regimens.
5 Ways to Improve Medication Adherence for Pediatric ADHD Clinical Trial Participants
Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental behavioral disorder in childhood and adolescence. The worldwide pooled prevalence in this population is estimated to be 6-8%, with estimates varying depending on measurement methodology.
Clinical Study Teams Find Value in High-Fidelity Data Sources
With the largest attendance in its 25-year history, the Society for Clinical Data Management (SCDM) Annual Conference was another sign of growing digital innovation in clinical trials. Called "The Festival of Clinical Data Science," the event filled the week of Oct. 8-11, 2023, in San Diego, CA, with fresh perspectives, deep insights, and good engagement among more than 1,000 professional colleagues.
Neuropathic Pain Trials Combine Drug Adherence, E-Diaries for Personalized Interventions
The percentage of people in pain around the world rose from 26.3% in 2009 to 32.1% in 2021, an increase of approximately 500 million people. Persistent pain in the U.S. is estimated to affect over 100 million adults at any given time, and carries direct and indirect costs of over $600 billion annually.
Psoriasis Clinical Trials Aim to Improve Disease Management, Drug Adherence
Psoriasis is an immune-mediated inflammatory disease, with a chronic relapsing-remitting course, which affects 2–3% of the worldwide population. This blog provides a brief overview of medication adherence in psoriasis, a snapshot of the psoriasis clinical trial landscape, and a look at technology used to improve dosing performance in psoriasis clinical research.